Cell-based therapies

Careful safety assessment for minimization of risk

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Cell therapy can be numbered among the novel biologic therapeutics that will increase our ability to cure human disease in the years to come. While the general feeling is that in vivo use of ex-vivo expanded cellular products is relatively safe, the attempt at augmenting potency have increased the risk for adverse events. Future efforts are warranted to better characterize cellular products, and collect and analyze clinical trial outcomes through national databases, to identify risks connected to their in vivo use.

Original languageEnglish
Pages (from-to)710-712
Number of pages3
JournalCytotherapy
Volume12
Issue number6
DOIs
Publication statusPublished - Oct 2010

Fingerprint

Cell- and Tissue-Based Therapy
Safety
Aptitude
Emotions
Clinical Trials
Databases
Therapeutics

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Molecular Medicine

Cite this

Cell-based therapies : Careful safety assessment for minimization of risk. / Comoli, Patrizia.

In: Cytotherapy, Vol. 12, No. 6, 10.2010, p. 710-712.

Research output: Contribution to journalArticle

@article{6a67655ff34e4f9e82522ea8fc7c7e30,
title = "Cell-based therapies: Careful safety assessment for minimization of risk",
abstract = "Cell therapy can be numbered among the novel biologic therapeutics that will increase our ability to cure human disease in the years to come. While the general feeling is that in vivo use of ex-vivo expanded cellular products is relatively safe, the attempt at augmenting potency have increased the risk for adverse events. Future efforts are warranted to better characterize cellular products, and collect and analyze clinical trial outcomes through national databases, to identify risks connected to their in vivo use.",
author = "Patrizia Comoli",
year = "2010",
month = "10",
doi = "10.3109/14653249.2010.517392",
language = "English",
volume = "12",
pages = "710--712",
journal = "Cytotherapy",
issn = "1465-3249",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Cell-based therapies

T2 - Careful safety assessment for minimization of risk

AU - Comoli, Patrizia

PY - 2010/10

Y1 - 2010/10

N2 - Cell therapy can be numbered among the novel biologic therapeutics that will increase our ability to cure human disease in the years to come. While the general feeling is that in vivo use of ex-vivo expanded cellular products is relatively safe, the attempt at augmenting potency have increased the risk for adverse events. Future efforts are warranted to better characterize cellular products, and collect and analyze clinical trial outcomes through national databases, to identify risks connected to their in vivo use.

AB - Cell therapy can be numbered among the novel biologic therapeutics that will increase our ability to cure human disease in the years to come. While the general feeling is that in vivo use of ex-vivo expanded cellular products is relatively safe, the attempt at augmenting potency have increased the risk for adverse events. Future efforts are warranted to better characterize cellular products, and collect and analyze clinical trial outcomes through national databases, to identify risks connected to their in vivo use.

UR - http://www.scopus.com/inward/record.url?scp=77957303923&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957303923&partnerID=8YFLogxK

U2 - 10.3109/14653249.2010.517392

DO - 10.3109/14653249.2010.517392

M3 - Article

VL - 12

SP - 710

EP - 712

JO - Cytotherapy

JF - Cytotherapy

SN - 1465-3249

IS - 6

ER -